Arcellx, Inc. announced new interim clinical data from its Phase 1 expansion study of CART-ddBCMA in patients with multiple myeloma and upcoming presentation at the ASH Annual Meeting.
AI Assistant
ARCELLX INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.